Pure Global

A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye - Trial NCT06296966

Access comprehensive clinical trial information for NCT06296966 through Pure Global AI's free database. This Phase 2 trial is sponsored by Vanda Pharmaceuticals and is currently Recruiting. The study focuses on Dry Eye. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06296966
Phase 2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06296966
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
A Four-Week, Double-Masked, Randomized, Placebo-Controlled, Phase 2, Evaluation of the Safety and Efficacy of VSJ-110 Ophthalmic Solution in the Treatment of Dry Eye

Study Focus

Dry Eye

VSJ-110

Interventional

drug

Sponsor & Location

Vanda Pharmaceuticals

Andover, United States of America

Timeline & Enrollment

Phase 2

Feb 29, 2024

Jul 01, 2024

40 participants

Primary Outcome

Schirmer's Tear Test

Summary

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to
 placebo in the treatment of dry eye.

ICD-10 Classifications

Ocular pain
Avulsion of eye
Other corneal deformities
Corneal ulcer
Dry mouth, unspecified

Data Source

ClinicalTrials.gov

NCT06296966

Non-Device Trial